Proteus Digital Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proteus Digital Health, Inc.
Analysts are waiting to see how the drugs giant intends to drive growth for new products, with a particular interest in the prospects for the PARP inhibitor Zejula and the single-pill, two-drug HIV therapy Dovato.
The new alliance is focused on developing a "digital therapeutic" for the treatment of depression. They hope it will take its place as an effective option among current drug and other cognitive therapies.
“There’s an app for that” could take on added significance under a new alliance for a digital therapeutic for the treatment of depression, in which the partners hope the novel approach will take its place as an effective option among current drug and other cognitive therapies.
Bringing A Digital Pill To Oncology: Proteus Partners With Health System To Prescribe Sensor-Enabled Chemotherapy
Proteus Digital Health announced a new partnership with Fairview Health Services and the University of Minnesota Health to prescribe capecitabine, a common chemotherapy drug, encapsulated with a sensor to colorectal cancer patients. Under the program, patients are prescribed the "digital capecitabine" and will be monitored remotely to see when they take their meds and for other health data. The goal is to improve patients' treatment adherence and improve outcomes.
- Drug Delivery
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Proteus Biomedical Inc.